



## Clinical trial results:

### A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Erlotinib as First-Line Treatment for Patients with Met-Positive Unresectable Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation

#### Summary

EudraCT number	2013-000868-29
Trial protocol	ES DE IT FR
Global end of trial date	05 February 2015

#### Results information

Result version number	v1 (current)
This version publication date	07 April 2016
First version publication date	07 April 2016

#### Trial information

##### Trial identification

Sponsor protocol code	GO28758
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01887886
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com
Scientific contact	Roche Trial Information Hotline, F. Hoffmann-La Roche AG, +41 61 6878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 February 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	05 February 2015
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Participants with previously untreated MET-positive NSCLC carrying an activating epidermal growth factor receptor (EGFR) mutation were treated with onartuzumab plus erlotinib (versus placebo plus erlotinib) to evaluate the safety and efficacy of the two-drug combination. The primary efficacy objective was to compare progression-free survival (PFS) as assessed by the investigator.

Protection of trial subjects:

This study was conducted in full conformance with the International Conference on Harmonisation (ICH) E6 guideline for Good Clinical Practice and the principles of the Declaration of Helsinki, or the laws and regulations of the country in which the research was conducted, whichever afforded the greater protection to the individual. The study has complied with the requirements of the ICH E2A guideline (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). Study sites in the United States (US) or under a US Investigational New Drug application (IND) complied with US Food and Drug Administration (FDA) regulations and applicable local, state, and federal laws. Studies conducted in the European Union (EU)/European Economic Area (EEA) complied with the EU Clinical Trial Directive (2001/20/EC).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	16 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	France: 2
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Korea, Republic of: 1
Country: Number of subjects enrolled	United States: 4
Worldwide total number of subjects	10
EEA total number of subjects	5

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	6
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Screening tests and evaluations were performed within 28 days prior to Day 1 of Cycle 1. All screening evaluations were required to be completed and reviewed before randomization to confirm that participants met all eligibility criteria.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Subject

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Onartuzumab + Erlotinib

Arm description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received onartuzumab as 15 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 milligrams (mg) orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Arm type	Experimental
Investigational medicinal product name	Erlotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1.

Investigational medicinal product name	Onartuzumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Onartuzumab was given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.

<b>Arm title</b>	Placebo + Erlotinib
------------------	---------------------

Arm description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received placebo (matched to onartuzumab) via IV infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Erlotinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1.

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was administered via IV infusion on Day 1 of each 21-day cycle.

<b>Number of subjects in period 1</b>	Onartuzumab + Erlotinib	Placebo + Erlotinib
Started	5	5
Completed	0	0
Not completed	5	5
Consent withdrawn by subject	1	-
Study terminated by Sponsor	3	3
Death	1	2

## Baseline characteristics

### Reporting groups

Reporting group title	Onartuzumab + Erlotinib
-----------------------	-------------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received onartuzumab as 15 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 milligrams (mg) orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Reporting group title	Placebo + Erlotinib
-----------------------	---------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received placebo (matched to onartuzumab) via IV infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Reporting group values	Onartuzumab + Erlotinib	Placebo + Erlotinib	Total
Number of subjects	5	5	10
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	71.2 ± 10.8	61 ± 9.1	-
Gender categorical Units: Subjects			
Female	4	5	9
Male	1	0	1

## End points

### End points reporting groups

Reporting group title	Onartuzumab + Erlotinib
-----------------------	-------------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received onartuzumab as 15 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 milligrams (mg) orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Reporting group title	Placebo + Erlotinib
-----------------------	---------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received placebo (matched to onartuzumab) via IV infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

### Primary: PFS

End point title	PFS <sup>[1]</sup>
-----------------	--------------------

End point description:

PFS was defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death. Disease progression was defined as greater than or equal to ( $\geq$ ) 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including Baseline. Endpoint data were to be analyzed using Kaplan-Meier methodology.

End point type	Primary
----------------	---------

End point timeframe:

Tumor assessments every 6 weeks for the first year, then every 9 weeks until disease progression (up to 14 months overall)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The data were not analyzed because the development program was terminated by the Sponsor.

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[2]</sup>	0 <sup>[3]</sup>		
Units: months				
median (full range (min-max))	( to )	( to )		

Notes:

[2] - The data were not analyzed because the development program was terminated by the Sponsor.

[3] - The data were not analyzed because the development program was terminated by the Sponsor.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS was defined as the time from date of randomization until death from any cause. Endpoint data were to be analyzed using Kaplan-Meier methodology.

End point type	Secondary
----------------	-----------

End point timeframe:

Continuously during treatment (up to 14 months) and every 3 months until withdrawal, death, or study end (up to 14 months overall)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	0 <sup>[5]</sup>		
Units: months				
median (full range (min-max))	( to )	( to )		

Notes:

[4] - The data were not analyzed because the development program was terminated by the Sponsor.

[5] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants with Partial or Complete Response According to RECIST v1.1

End point title	Percentage of Participants with Partial or Complete Response According to RECIST v1.1
-----------------	---

End point description:

Partial response was defined as  $\geq 30\%$  decrease in the sum of diameters of target lesions, taking as reference the Baseline sum of diameters. Complete response was defined as disappearance of all target lesions. The overall response rate (ORR) was to be determined as the percentage of participants with meeting either set of criteria during the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Tumor assessments every 6 weeks for the first year, then every 9 weeks until disease progression (up to 14 months overall)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>		
Units: percentage of participants				
number (not applicable)				

Notes:

[6] - The data were not analyzed because the development program was terminated by the Sponsor.

[7] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point



## Secondary: Time to Deterioration (TTD) in Lung Cancer Symptoms

End point title	Time to Deterioration (TTD) in Lung Cancer Symptoms
-----------------	---

End point description:

TTD was defined the time from Baseline to first increase (i.e. worsening) in lung cancer symptoms of cough, dyspnea, chest pain, or arm/shoulder pain. Symptom worsening was defined as a  $\geq 10$ -point increase in the individual item score on the European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire (QLQ-C30) or EORTC 13-Item Lung Cancer Module (QLQ-LC13). Most questions from the QLQ-C30 and QLQ-LC13 use a 4-point scale (1 equals [=] 'not at all' to 4 = 'very much') except for two questions from the QLQ-C30 that use a 7-point scale (1 = 'very poor' to 7 = 'excellent'). Regardless, item scores are transformed to a scale from 0 to 100, where higher scores indicate a greater degree of symptoms.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, every 3 months during treatment (up to 14 months), within 30 days of last dose, and 3 months after last dose (up to 14 months overall)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>		
Units: months				
median (full range (min-max))	( to )	( to )		

Notes:

[8] - The data were not analyzed because the development program was terminated by the Sponsor.

[9] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from Baseline in EORTC QLQ-C30 Domain Scores

End point title	Change from Baseline in EORTC QLQ-C30 Domain Scores
-----------------	---

End point description:

The EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions use a 4-point scale (1 equals [=] 'not at all' to 4 = 'very much') except for two questions that use a 7-point scale (1 = 'very poor' to 7 = 'excellent'). Regardless, item scores are transformed to a scale from 0 to 100, where higher scores indicate better level of functioning or a greater degree of symptoms.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of treatment (up to 14 months)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>		
Units: units on a scale				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[10] - The data were not analyzed because the development program was terminated by the Sponsor.

[11] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline EORTC QLQ-LC13 Domain Scores

End point title	Change from Baseline EORTC QLQ-LC13 Domain Scores
-----------------	---

End point description:

The QLQ-LC13 consists of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprise one 3-item scale for dyspnea and ten single-item symptom and side effects scales (cough, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Participants are asked to recall symptoms within the prior week. Questions use a 4-point scale (1 = 'not at all' to 4 = 'very much'). Item scores are transformed to a scale from 0 to 100, where higher scores indicate a greater degree of symptoms.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to end of treatment (up to 14 months)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>		
Units: units on a scale				
arithmetic mean (standard deviation)	( )	( )		

Notes:

[12] - The data were not analyzed because the development program was terminated by the Sponsor.

[13] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Area Under the Concentration-Time Curve (AUC) of Onartuzumab

End point title	Area Under the Concentration-Time Curve (AUC) of Onartuzumab
-----------------	--

End point description:

Serum samples were collected at various timepoints to assess the pharmacokinetics of onartuzumab. The AUC was to be determined for each participant, averaged across all participants, and expressed in micrograms by hours per milliliter (mcg\*h/mL).

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (0 hours) on Day 1 of Cycles 1, 2, 4; post-dose (1 hour after end of infusion) on Day 1 of Cycle 1; and within 30 days of last dose (up to 14 months overall)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[14]</sup>	0 <sup>[15]</sup>		
Units: mcg*h/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[14] - The data were not analyzed because the development program was terminated by the Sponsor.

[15] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Minimum Observed Concentration (Cmin) of Onartuzumab

End point title	Minimum Observed Concentration (Cmin) of Onartuzumab
End point description: Serum samples were collected at various timepoints to assess the pharmacokinetics of onartuzumab. The Cmin was to be determined for each participant, averaged across all participants, and expressed in micrograms per milliliter (mcg/mL).	
End point type	Secondary
End point timeframe: Pre-dose (0 hours) on Day 1 of Cycles 1, 2, 4	

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[16]</sup>	0 <sup>[17]</sup>		
Units: mcg/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[16] - The data were not analyzed because the development program was terminated by the Sponsor.

[17] - The data were not analyzed because the development program was terminated by the Sponsor.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maximum Observed Concentration (Cmax) of Onartuzumab

End point title	Maximum Observed Concentration (Cmax) of Onartuzumab
End point description: Serum samples were collected to assess the pharmacokinetics of onartuzumab. The Cmax was to be determined for each participant, averaged across all participants, and expressed in mcg/mL.	
End point type	Secondary
End point timeframe: Post-dose (1 hour after end of infusion) on Day 1 of Cycle 1	

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[18]</sup>	0 <sup>[19]</sup>		
Units: mcg/mL				
arithmetic mean (standard deviation)	()	()		

Notes:

[18] - The data were not analyzed because the development program was terminated by the Sponsor.

[19] - The data were not analyzed because the development program was terminated by the Sponsor.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Onartuzumab

End point title	Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Onartuzumab
-----------------	---

End point description:

Serum samples were collected at various timepoints to assess for the presence of ATAs to onartuzumab. The percentage of participants who demonstrated ATAs at any time was to be determined.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose (0 hours) on Day 1 of Cycles 1 and 4 and within 30 days of last dose (up to 14 months overall)

End point values	Onartuzumab + Erlotinib	Placebo + Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[20]</sup>	0 <sup>[21]</sup>		
Units: percentage of participants				
number (not applicable)				

Notes:

[20] - The data were not analyzed because the development program was terminated by the Sponsor.

[21] - The data were not analyzed because the development program was terminated by the Sponsor.

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Continuously during treatment (up to 14 months) and within 30 days of last dose (up to 14 months overall)

Adverse event reporting additional description:

Safety Population: All participants who received at least one dose of study medication.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.0
--------------------	------

### Reporting groups

Reporting group title	Onartuzumab + Erlotinib
-----------------------	-------------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received onartuzumab as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Reporting group title	Placebo + Erlotinib
-----------------------	---------------------

Reporting group description:

Participants with MET receptor-positive, unresectable Stage IIIB or Stage IV NSCLC carrying an activating EGFR mutation received placebo (matched to onartuzumab) via IV infusion on Day 1 of each 21-day cycle. Erlotinib tablets were administered as 150 mg orally once daily beginning on Day 1 of Cycle 1. Treatment continued until disease progression, unacceptable toxicity, withdrawal, death, or termination of the study.

Serious adverse events	Onartuzumab + Erlotinib	Placebo + Erlotinib	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 5 (40.00%)	1 / 5 (20.00%)	
number of deaths (all causes)	1	2	
number of deaths resulting from adverse events			
Vascular disorders			
Raynaud's phenomenon			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Encephalopathy			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Musculoskeletal and connective tissue			

disorders			
Arthritis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Onartuzumab + Erlotinib	Placebo + Erlotinib	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 5 (100.00%)	5 / 5 (100.00%)	
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Axillary pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Chest pain			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Chills			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Fatigue			
subjects affected / exposed	3 / 5 (60.00%)	1 / 5 (20.00%)	
occurrences (all)	3	2	
Gait disturbance			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Mucosal inflammation			

subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 4	0 / 5 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 2	1 / 5 (20.00%) 1	
Dyspnoea subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Dyspnoea exertional subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Haemoptysis subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Pleural effusion subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Rhinorrhoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Wheezing subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Anxiety subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Depression			

subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Insomnia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 5 (20.00%) 1	
Investigations Transaminases increased subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Nervous system disorders Carpal tunnel syndrome subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Headache subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	2 / 5 (40.00%) 2	
Paraesthesia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Tremor subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Visual field defect subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Eye disorders Glaucoma subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Vision blurred subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Gastrointestinal disorders Abdominal distension subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Abdominal pain			



subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	1
Abdominal pain upper		
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	1	0
Anal fissure		
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	1
Anorectal discomfort		
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	1	0
Constipation		
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	2
Diarrhoea		
subjects affected / exposed	2 / 5 (40.00%)	3 / 5 (60.00%)
occurrences (all)	2	4
Dry mouth		
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	1	0
Dysphagia		
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	1
Gastrointestinal pain		
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	1	0
Gastrooesophageal reflux disease		
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)
occurrences (all)	1	0
Nausea		
subjects affected / exposed	2 / 5 (40.00%)	5 / 5 (100.00%)
occurrences (all)	2	5
Stomatitis		
subjects affected / exposed	0 / 5 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	2
Toothache		

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Vomiting subjects affected / exposed occurrences (all)	2 / 5 (40.00%) 3	1 / 5 (20.00%) 1	
Skin and subcutaneous tissue disorders			
Acne subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 2	1 / 5 (20.00%) 1	
Alopecia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 5 (20.00%) 1	
Dermatitis acneiform subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Dry skin subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 5 (40.00%) 2	
Rash subjects affected / exposed occurrences (all)	4 / 5 (80.00%) 7	3 / 5 (60.00%) 3	
Pruritus subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 5 (0.00%) 0	
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	1 / 5 (20.00%) 1	
Musculoskeletal and connective tissue disorders			
Back pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	2 / 5 (40.00%) 2	
Muscle spasms subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	1 / 5 (20.00%) 1	
Musculoskeletal chest pain			

subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Infections and infestations			
Conjunctivitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Nasopharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Oral candidiasis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Paronychia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Rhinitis			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Tooth infection			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	
Urinary tract infection			
subjects affected / exposed	2 / 5 (40.00%)	1 / 5 (20.00%)	
occurrences (all)	3	3	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 5 (20.00%)	2 / 5 (40.00%)	
occurrences (all)	1	2	
Hypoalbuminaemia			
subjects affected / exposed	1 / 5 (20.00%)	1 / 5 (20.00%)	
occurrences (all)	1	1	
Hypocalcaemia			

subjects affected / exposed	1 / 5 (20.00%)	0 / 5 (0.00%)	
occurrences (all)	1	0	
Vitamin D deficiency			
subjects affected / exposed	0 / 5 (0.00%)	1 / 5 (20.00%)	
occurrences (all)	0	1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
05 February 2015	The study was terminated following concerns that the addition of onartuzumab to erlotinib could have the potential to shorten survival in previously untreated patients with MET-positive EGFR-mutant locally advanced or metastatic NSCLC.	-

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Because the study was terminated early, the study results were reported in an abbreviated format that did not include analysis of efficacy or pharmacokinetic data. Only safety results are reported herein.
--

Notes: